



CAVA HEALTHCARE INC.
PRESS RELEASE

CAVA HEALTHCARE ANNOUNCES ISSUANCE OF CANADIAN PATENT ON CURCUPHENOL COMPOUNDS FOR INCREASING IMMUNE DESTRUCTION OF METASTATIC CANCERS

Increases Immunogenicity of Cells, Provides New Treatment Options for Metastatic Cancers

Vancouver, British Columbia, November 28, 2023 – Cava Healthcare Inc. (Cava), a biopharmaceutical company, is pleased to announce the issuance of its Canadian Patent for curcuphenol compounds to treat cancer. These compounds are specifically designed to enhance the immune system's capacity to eradicate metastatic cancers. Considering that metastatic cancer accounts for approximately 90% of cancer-related fatalities, the need for innovative drugs disrupting the transition from primary to metastatic stages is crucial. Ethnobotanical studies highlight turmeric and cumin as potential remedies for cancer, primarily attributed to curcuminoids such as curcuphenol. However, further research was needed to pinpoint the specific molecular entities responsible for distinct medicinal benefits. The issued patent elucidates methods for utilizing curcuphenol compounds to elevate the immunogenicity of metastatic cancer cells that leads to their subsequent immune destruction. Furthermore, it encompasses pharmaceutical composition claims pertaining to novel curcuphenol compounds, along with methods of their application. These methods include the treatment of various cancers, either as stand-alone therapies or in conjunction with other therapeutic approaches.

Dr. Wilfred Jefferies, Cava's Chief Scientific Officer, stated "This patent significantly enhances Cava's intellectual property in the field of cancer treatment. The restoration of immunosurveillance is a crucial step in enabling the body to identify and eliminate cancer cells. We anticipate the adoption of the compounds and methods outlined in this patent by clinicians, marking a positive advancement in cancer care."

The issuance of this patent in Canada adds to the jurisdictions in which Cava has received patent coverage. The issuance of this patent is a key step for Cava in safeguarding the commercial viability of drugs for treating cancer.

For further information, please contact Adrian Wade at news@cavahealthcare.ca.

On Behalf of the Board of Directors

Adrian Wade, Ph.D.
COO and Director
Investor Relations and Corporate Communications

CAVA IS FOCUSED ON ENHANCING OPTIMAL HEALTH BY PREDICTING, PREVENTING AND ALLEVIATING DISEASE

Cava is a specialty biotechnology company focused on advancing drug development to address unmet medical needs in neurodegeneration, inflammation, and restoration of immune function. The Company has a patent protected portfolio of intellectual property and technology, concentrated on the development of a treatment for Alzheimer's Disease and various oncology related biomarkers and treatments.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this press release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations, and orientations regarding the future including, without limitation, matters related to the Company's current and planned research and development programs, including in respect of the prosecution and maintenance of the patent portfolio, and the Company's prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "plans", "expects", "may", "intends", "anticipates", "believes", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding the Company, including, without limitation, expected growth, results of operations and research and development activities (including in respect of the patent portfolio), results of operations, performance, industry trends, growth opportunities, and that the Company will be able to obtain the financing required to carry out its planned future business activities, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights it needs to carry out its future business activities.

Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the actual results of research and development programs, the inability of the Company, to, among other things, protect its intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, commercialize any therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research and development programs as planned, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the Company's industries may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this press release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, intentions, and assumptions contained in this press release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations intentions or assumptions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company's filings are available at www.sedar.com.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.